BR112012004105A2 - pró-fármacos de bisfosfonato - Google Patents

pró-fármacos de bisfosfonato

Info

Publication number
BR112012004105A2
BR112012004105A2 BR112012004105A BR112012004105A BR112012004105A2 BR 112012004105 A2 BR112012004105 A2 BR 112012004105A2 BR 112012004105 A BR112012004105 A BR 112012004105A BR 112012004105 A BR112012004105 A BR 112012004105A BR 112012004105 A2 BR112012004105 A2 BR 112012004105A2
Authority
BR
Brazil
Prior art keywords
bisphosphonate prodrugs
bisphosphonate
prodrugs
Prior art date
Application number
BR112012004105A
Other languages
English (en)
Portuguese (pt)
Inventor
Kratz Felix
Hochdoerffer Katrin
Original Assignee
Ktb Tumorforschungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ktb Tumorforschungsgesellschaft Mbh filed Critical Ktb Tumorforschungsgesellschaft Mbh
Publication of BR112012004105A2 publication Critical patent/BR112012004105A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012004105A 2009-08-25 2010-08-24 pró-fármacos de bisfosfonato BR112012004105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09010871A EP2289558A1 (de) 2009-08-25 2009-08-25 Bisphosphonat-Prodrugs
PCT/EP2010/005187 WO2011023367A2 (en) 2009-08-25 2010-08-24 Bisphosphonate-prodrugs

Publications (1)

Publication Number Publication Date
BR112012004105A2 true BR112012004105A2 (pt) 2017-06-20

Family

ID=41396494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004105A BR112012004105A2 (pt) 2009-08-25 2010-08-24 pró-fármacos de bisfosfonato

Country Status (5)

Country Link
US (1) US8778914B2 (de)
EP (3) EP2289558A1 (de)
CN (1) CN102665767B (de)
BR (1) BR112012004105A2 (de)
WO (1) WO2011023367A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320803B2 (en) 2011-02-24 2016-04-26 Ktb Tumorforschungsgesellschaft Mbh Bisphosphonate-prodrugs
FR2973378B1 (fr) * 2011-03-28 2013-10-04 Atlanthera Derives d'acide hydroxybisphosphonique bifonctionnels
TWI616531B (zh) 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
WO2015021044A1 (en) * 2013-08-05 2015-02-12 University Of Rochester Compositions and methods for stimuli-responsive release of a therapeutic agent
GB201319363D0 (en) 2013-11-01 2013-12-18 Uni I Oslo Compounds
US9499800B2 (en) * 2013-12-26 2016-11-22 Regents Of The University Of Minnesota Methods of making and using chemically self assembled-nanorings
EP3160513B1 (de) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharidderivat einer toxischen nutzlast und antikörperkonjugate davon
FR3028762B1 (fr) 2014-11-20 2017-01-06 Atlanthera Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
JP6948708B2 (ja) 2015-06-19 2021-10-13 センチュリオン バイオファーマ コーポレイション 薬物制御放出のための送達系
EP4344747A3 (de) 2017-11-30 2024-07-03 LadRx Corporation Albuminbindende prodrugs von auristatin-e-derivaten
AU2018375788A1 (en) 2017-11-30 2020-07-09 Ladrx Corporation Maytansinoid-based drug delivery systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511811A (ja) * 1997-02-13 2001-08-14 ボーン ケア インターナショナル インコーポレイテッド ビタミンｄ化合物の標的治療放出
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
WO2002083150A1 (en) 2001-04-10 2002-10-24 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
BRPI0707516A2 (pt) 2006-02-06 2011-05-10 Cypress Bioscience Inc composiÇÕes que compreendem um bisfosfonato e um antifolato
WO2008077241A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
ES2704199T3 (es) * 2007-02-16 2019-03-14 Vergell Medical S A Profármacos de doble acción
US9216228B2 (en) * 2007-02-16 2015-12-22 KTB Tumorforschungsgesellschaft MBM Receptor and antigen targeted prodrug
FR2926081B1 (fr) * 2008-01-03 2010-02-19 Univ Nantes Derives d'acide hydroxy-bisphosphonique comme vecteur ciblant le tissu osseux
EP2268315B1 (de) * 2008-03-31 2019-07-31 Freie Universität Berlin Wirkstoffkonjugate mit polyglycerolen
EP2303288A4 (de) * 2008-05-22 2015-04-22 Univ Ramot Konjugate eines polymers, eines bisphosphonats und eines anti-angiogenese-mittels und ihre verwendungen bei der behandlung und kontrolle von erkrankungen im zusammenhang mit knochen

Also Published As

Publication number Publication date
EP2289558A1 (de) 2011-03-02
WO2011023367A3 (en) 2011-08-18
EP3384937A2 (de) 2018-10-10
EP3384937A3 (de) 2019-01-16
EP2470215B1 (de) 2018-04-25
US20120165296A1 (en) 2012-06-28
CN102665767B (zh) 2016-05-04
US8778914B2 (en) 2014-07-15
WO2011023367A2 (en) 2011-03-03
CN102665767A (zh) 2012-09-12
EP2470215A2 (de) 2012-07-04

Similar Documents

Publication Publication Date Title
FIC20220051I1 (fi) Olipudaasi alfa
SI2320908T1 (sl) Predzdravila dolutegravirja
BR112012002168A2 (pt) profármacos compreendendo um conjugado ligador de insulina
BR112012004105A2 (pt) pró-fármacos de bisfosfonato
BRPI1005525A2 (pt) compostos de azaazuleno
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
EP2433940A4 (de) Spiroimidazolonderivat
BR112012005598A2 (pt) profármacos de guanfacina
BRPI1014802A2 (pt) pró-fármacos de triptolida.
EP2397480A4 (de) Diazepinedionederivate
BR112012004376A2 (pt) estimativa do segmento de audiência
BRPI1007196A2 (pt) profármacos e derivado de espiroindolinona
EP2401281A4 (de) Pyrimidinpyrimidoindazolderivat
FR2947857B1 (fr) Agencement de deshuileur
EP2492266A4 (de) 5-hydroxypyrimidin-4-carboxamidderivat
EP2509287A4 (de) Schiebe- und kippmechanismus
ITPD20090053U1 (it) Paradordi per banchine
BR112012006693A2 (pt) combinação
DK2267242T3 (da) Udskiftningskonsol
EP2463290A4 (de) Thienoxazepinderivat
BRPI1007893A2 (pt) derivado de cianopirimidina
EP2344503A4 (de) 5-azaindol-bisphosphonate
BRPI1009199A2 (pt) compostos de pirazinoisoquinolina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), A61P 35/00 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements